Table 3 Effect sizes and changes in clinical outcome from baseline to final visit (N = 27)
| Â | Intake (t1) | 3-month follow-up (t4) | |||
|---|---|---|---|---|---|
| Â | Mean (SD) | Median (range) | Mean (SD) | Median (range) | Effect size |
BDI Total | 30.44 (7.85) | 29 (14 - 44) | 20.67 (10.05) | 19 (3-43) | 1.09 |
PCL Total | 56.11 (12.66) | 55 (34-87) | 46.85 (13.53) | 46 (23-67) | 0.90 |
PCL Reexperiencing | 15.00 (4.42) | 15 (7-25) | 12.61 (4.72) | 12 (5-22) | 0.57 |
PCL Avoidance | 23.40 (5.22) | 23 (14-34) | 21.05 (6.02) | 21 (10-31) | 0.38 |
PCL Hyperarousal | 16.04 (4.02) | 16 (10-22) | 13.96 (4.32) | 14 (5-21) | 0.48 |